|
|
Profile
|
Delegates :
Ayano Fukuhara |
|
Incorporated :
August 1 , 2006 |
Paid in Capital :
430 Million yen |
Employees :
23 members |
Address :
7F Erimo Building 2-1-1 Senba-Nishi, Minoh OSAKA
〒562-0036
|
TEL/FAX :
+81-6-6155-7835 / |
URL：
https://u-medico.co.jp/?utm_source=bioventure&utm_medium=referral |
Attachment :
|
Mission/Background :
U-Medico Inc. is a contract research organization (CRO) founded under the leadership of Professor Susumu Uchiyama of the School of Engineering at Osaka University. The company specializes in the characterization, formulation development, process development, and quality analysis of biopharmaceuticals and viral vectors for gene and cell therapies. Leveraging deep scientific expertise and flexible responsiveness, we deliver reliable and value-added analytical and manufacturing support. With a GMP-compliant framework in place, we provide high-quality services based on global standards, contributing to the advancement of cutting-edge medicine and the improvement of public health. |
|
Technology & Business
|
■Characterization of Biopharmaceuticals
Analysis of particles and aggregates contained in biopharmaceuticals, interaction analysis, and structural analysis.
■Formulation Development for Biopharmaceuticals and Gene Therapy Viral Vectors
Pre-formulation studies, container-closure system compatibility evaluation, and stability testing.
■Quality Analysis of Gene Therapy Viral Vectors
Full-to-empty particle ratio of AAV vectors, structural analysis, and viral genome titer determination.
■Manufacturing of Gene Therapy Viral Vectors
Production of highly concentrated and highly purified AAV vectors.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Aggregate Analysis of Biopharmaceuticals (GMP-compliant available)
|
Service/Marketing
|
Quantitative analysis of aggregates in biopharmaceuticals across a wide size range from nanometers to tens of micrometers.
|
Expanding of the contract service
|
Structural Analysis of Biopharmaceuticals
|
Service/Marketing
|
Post-translational modification analysis by LC-MS/MS and epitope mapping by HDX-MS to identify protein interaction sites.
|
Expanding of the contract service
|
Formulation Development for Biopharmaceuticals and Gene Therapy Viral Vectors
|
Service/Marketing
|
Development of stable formulations through efficient formulation studies utilizing physicochemical parameters.
|
Expanding of the contract service
|
Stability Testing of Biopharmaceuticals
|
Service/Marketing
|
Stability testing of biopharmaceuticals based on ICH guidelines, including quality testing at each time point.
|
Expanding of the contract service
|
Determination of Full-to-Empty Particle Ratio in Gene Therapy Viral Vectors (GMP-compliant available)
|
Service/Marketing
|
Determination of empty-to-full (EF) particle ratios using analytical ultracentrifugation (AUC), mass photometry (MP), and other
|
Expanding of the contract service
|
|
Highlights
|
In April 2025, we opened a new facility to meet the growing demand in the field of gene and cell therapy, offering GMP-compliant contract analytical services. This enables us to provide more advanced and reliable quality analysis. Additionally, we have launched a new manufacturing service for AAV viral vectors, steadily expanding our business scope.
|
|
Hot news
|
In October 2024, we entered into a capital and business alliance with Shimadzu Corporation and AS ONE Corporation.
|
|
Alliance strategy
|
We are seeking partnerships with biopharmaceutical manufacturing companies.
|
|
|